ReviewJournal of clinical tuberculosis and other mycobacterial diseases2026
Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies.
Review in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting macrophage metabolic checkpoints: a host-directed strategy to overcome drug tolerance in tuberculosis.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the leading infectious cause of death globally. Although effective treatments are available, treatment length, drug toxicity, and the emergence of drug-resistant strains have challenged TB control efforts. Current clinical trials are focused on developing shorter, safer, and more effective regimens that incorporate both new and repurposed agents for the treatment of TB. This narrative review provides an overview of current and emerging treatment options for drug-susceptible, drug-resistant, and latent TB based on recent clinical trials and WHO guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.